We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

23 hedge funds and large institutions have $4.3M invested in Viridian Therapeutics in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.48% less ownership

Funds ownership: 2.33% → 1.85% (-0.48%)

30% less funds holding

Funds holding: 33 → 23 (-10)

46% less capital invested

Capital invested by funds: $7.95M → $4.3M (-$3.65M)

75% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 12

83% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 6

Holders
23
Holders Change
-10
Holders Change %
-30.3%
% of All Funds
0.45%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
1
Reduced
6
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$178K
2
WS
Wedbush Securities
California
+$60.3K
3
VF
Virtu Financial
New York
+$35.2K

Top Sellers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
-$1.01M
2
Goldman Sachs
Goldman Sachs
New York
-$152K
3
Millennium Management
Millennium Management
New York
-$151K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$150K
5
ARTA
A.R.T. Advisors
New York
-$16K
Name Holding Trade Value Shares
Change 		Change in
Stake
AVA
1
Atlas Venture Advisors
Massachusetts
$1.51M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$1.39M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$312K – – –
Renaissance Technologies
4
Renaissance Technologies
New York
$223K +$178K +17,355 +128%
BlackRock
5
BlackRock
New York
$199K -$533 -52 -0.2%
JP Morgan Chase
6
JP Morgan Chase
New York
$153K – – –
6CM
7
683 Capital Management
New York
$139K -$1.01M -98,403 -84%
Millennium Management
8
Millennium Management
New York
$86K -$151K -14,724 -55%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$74K – – –
Point72 Asset Management
10
Point72 Asset Management
Connecticut
$48K – – –
WS
11
Wedbush Securities
California
$42K +$60.3K +5,880 New
GPFA
12
Game Plan Financial Advisors
Ohio
$28K +$40K +3,903 New
Goldman Sachs
13
Goldman Sachs
New York
$26K -$152K -14,872 -81%
VF
14
Virtu Financial
New York
$25K +$35.2K +3,432 New
Northern Trust
15
Northern Trust
Illinois
$22K – – –
Deutsche Bank
16
Deutsche Bank
Germany
$10K -$12.4K -1,212 -46%
ACP
17
Aveo Capital Partners
Colorado
$8K – – –
State Street
18
State Street
Massachusetts
$6K – – –
Citigroup
19
Citigroup
New York
$1K – – –
PAM
20
Panagora Asset Management
Massachusetts
$1K – – –
BNP Paribas Financial Markets
21
BNP Paribas Financial Markets
France
$74 -$1.96K -191 -95%
Dimensional Fund Advisors
22
Dimensional Fund Advisors
Texas
– -$150K -13,637 Closed
Invesco
23
Invesco
Georgia
– -$16K -1,448 Closed
ARTA
24
A.R.T. Advisors
New York
– -$16K -1,430 Closed
Bank of New York Mellon
25
Bank of New York Mellon
New York
– -$15K -1,349 Closed
1
2

VRDN Hedge Fund Activity: Q4 2019 in Review

23 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q4 2019, worth a combined $4.3M — down 46% from $7.95M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of VRDN and 3 opened new positions — a net loss of 9 holders — while 6 trimmed existing stakes and 1 added.

The largest buyer was Renaissance Technologies, adding an estimated $178K. The largest seller was 683 Capital Management, cutting an estimated $1.01M.

  • 23 institutional investors held Viridian Therapeutics (VRDN) as of Q4 2019, down from 33 in Q3 2019.
  • Funds reported $4.3M of Viridian Therapeutics stock for Q4 2019, down 46% quarter-over-quarter.
  • 3 funds opened new Viridian Therapeutics positions in Q4 2019 and 12 closed out, a net change of -9 holders.
  • The largest Viridian Therapeutics buyer in Q4 2019 was Renaissance Technologies, an estimated $178K added.
  • The largest Viridian Therapeutics seller in Q4 2019 was 683 Capital Management, an estimated $1.01M sold.

Based on aggregated 13F filings for Q4 2019.